Elon Musk (Bill Clark/CQ Roll Call via AP Images)
September 20, 2023 01:36 PM EDT
R&D
Pharma
FDA+

Elon Musk's brain-com­put­er pro­gram be­gins re­cruit­ing paral­y­sis pa­tients

Nicole DeFeudis

Editor

Elon Musk’s brain-com­put­er in­ter­face start­up is of­fi­cial­ly re­cruit­ing paral­y­sis pa­tients for its first in-hu­man tri­al.

Neu­ralink an­nounced Tues­day that it has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times